CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands		Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2021		$ 46	$ 368,852	$ (374,934)	$ (6,036)
Beginning balance (in shares) at Dec. 31, 2021	[1]	45,556,647
Issuance of common stock under the Sales Agreement, net		$ 4	4,157		4,161
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	3,841,479
Share-based compensation related to stock options			592		592
Share-based compensation related to restricted stock awards			954		954
Share-based compensation related to restricted stock awards (in shares)	[1]	759,482
Exercise of warrants			2		2
Exercise of warrants (in shares)	[1]	1,000
Net income (loss) for the period				(11,187)	(11,187)
Ending balance at Sep. 30, 2022		$ 50	374,557	(386,121)	(11,514)
Ending balance (in shares) at Sep. 30, 2022	[1]	50,158,608
Beginning balance at Jun. 30, 2022		$ 49	372,616	(382,554)	(9,889)
Beginning balance (in shares) at Jun. 30, 2022	[1]	48,712,952
Issuance of common stock under the Sales Agreement, net		$ 1	1,519		1,520
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	1,445,656
Share-based compensation related to stock options			298		298
Share-based compensation related to restricted stock awards			124		124
Net income (loss) for the period				(3,567)	(3,567)
Ending balance at Sep. 30, 2022		$ 50	374,557	(386,121)	(11,514)
Ending balance (in shares) at Sep. 30, 2022	[1]	50,158,608
Beginning balance at Dec. 31, 2022		$ 54	379,167	(389,861)	(10,640)
Beginning balance (in shares) at Dec. 31, 2022	[1]	53,790,167
Issuance of common stock under the Sales Agreement, net		$ 13	23,941		23,954
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	12,560,150
Convertible notes conversions		$ 5	7,778		7,783
Convertible notes conversions (in shares)	[1]	4,691,623
Share-based compensation related to stock options			1,195		1,195
Share-based compensation related to restricted stock awards		$ 1	886		887
Share-based compensation related to restricted stock awards (in shares)	[1]	1,371,362
Exercise of warrants			712		712
Exercise of warrants (in shares)	[1]	538,822
Net income (loss) for the period				14,356	14,356
Ending balance at Sep. 30, 2023		$ 73	413,679	(375,505)	38,247
Ending balance (in shares) at Sep. 30, 2023	[1]	72,952,124
Beginning balance at Jun. 30, 2023		$ 72	412,582	(373,653)	39,001
Beginning balance (in shares) at Jun. 30, 2023	[1]	71,580,762
Share-based compensation related to stock options			383		383
Share-based compensation related to restricted stock awards		$ 1	714		$ 715
Share-based compensation related to restricted stock awards (in shares)	[1]	1,371,362
Exercise of warrants (in shares)					0
Net income (loss) for the period				(1,852)	$ (1,852)
Ending balance at Sep. 30, 2023		$ 73	$ 413,679	$ (375,505)	$ 38,247
Ending balance (in shares) at Sep. 30, 2023	[1]	72,952,124

[1] Common stock, $0.001 par value; Authorized – as of September 30, 2023 and December 31, 2022 – 185,000,000 and 144,000,000 shares, respectively.